• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A Novel Anti-Thrombotic, Glenzocimab, in Covid-19 acute respiratory distress syndrome (Cov-ARDS).
Conclusion: The GARDEN study was set up to tackle a global Public Health emergency. Glenzocimab was safe in doses three times higher than used in stroke. Albeit efficacy was not shown, overall, GARDEN provides insights into Cov-ARDS.
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Pottecher, J., Sato, V. A. H., Pletan, Y., Comenducci, A., Desort-Henin, V., Jandrot-Perrus, M., Binay, S., Meilhoc, A., Avenard, G. Tags: 02.01 - Acute critical care Source Type: research

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00298-3. doi: 10.1016/S2213-2600(22)00298-3. Online ahead of print.ABSTRACTBACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patient...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Maria Luz Diaz Rafael Diaz Afzalhussein Yusufali Sanjib Kumar Sharma Wadea M Tarhuni Mohamed Hassany Alvaro Avezum Will Source Type: research

Risk contribution of comorbidities in hospitalized patients with Covid 19 pneumonia
Background: The Covid 19 pandemic has a vast socioeconomic impact worldwide. Obtaining information about the course of the disease is vital for better management.Aim: To assess the risk, comorbidities (CMs) and mortality in hospitalized patients with Covid 19 pneumonia.Methods: The information was gathered from the medical registry and statistical analysis was performed using SPSS.Results: A total of 337 patient were analyzed. Males were 197 (58,5%). Positive PCR results had 307 (91,1%) patients. Almost half of the patients were with respiratory failure on admission (47,1%). At least one comorbidity was found in 84,6%. Fro...
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Kyuchukov, N., Krachunov, I., Ivanova, Z., Ignatova-Danova, T., Glogovska, P., Pavlov, P., Popova, T., Ivanov, Y. Tags: Respiratory infections and bronchiectasis Source Type: research

Thromboembolic events in COVID-19 patients : A Tunisian case series study
Coronavirus disease 2019 (COVID-19) can lead to systemic coagulation activation and thrombotic complications(TC), which may lead to fatal outcomes if not diagnosed and managed appropriately.We aimed to report the incidence and characteristics of venous and arterial thrombotic complications(TC) in hospitalized patients with COVID-19 and to investigate the predictive factors of their occurrence.A retrospective study including 200 patients with COVID-19 confirmed by a reverse transcription polymerase chain reaction test, admitted between March 2020 and January 2021 in the pulmonary departement B at Abderrahman Mami Hospi...
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Louhaichi, S., Ferchichi, M., Khalfallah, I., Belkhir, S., Boubaker, N., Ammar, J., Hamdi, B., Hamzaoui, A. Tags: Respiratory infections and bronchiectasis Source Type: research

Controversies over the impact of the COVID-19 pandemic on patients with Pulmonary Arterial Hypertension
This study is a retrospective analysis of our PAH patients treated in 2020 compared to the dynamics of the last 12 years. We had 48 PAH patients, 51.72±16.64 years, 72.91% female. All patients had chronic anticoagulant therapy(58.33%) and/or antiplatelet; 33.33% had long term oxygen therapy. Three patients with secondary forms were confirmed with COVID-19, all hospitalized (6.25% infection rate versus 3.29% in general). One patient died(75 years with scleroderma, stroke), two patients were cured (mild forms). In total only three patients died in 2020. Surprisingly, compared with 2008-2019 (101 patients/ 41 deaths, 3...
Source: European Respiratory Journal - November 25, 2021 Category: Respiratory Medicine Authors: Bertici, N. S., Dobrescu, L., Pislaru, L., Marincu, I. Tags: Pulmonary hypertension Source Type: research

COVID-19 and Its Implications for Thrombosis and Anticoagulation
Semin Respir Crit Care Med DOI: 10.1055/s-0041-1722992Venous thromboembolism, occlusion of dialysis catheters, circuit thrombosis in extracorporeal membrane oxygenation (ECMO) devices, acute limb ischemia, and isolated strokes, all in the face of prophylactic and even therapeutic anticoagulation, are features of novel coronavirus disease 2019 (COVID-19) coagulopathy. It seems well established at this time that a COVID-19 patient deemed sick enough to be hospitalized, should receive at least prophylactic dose anticoagulation. However, should some hospitalized patients have dosage escalation to intermediate dose? Should some...
Source: Seminars in Respiratory and Critical Care Medicine - February 6, 2021 Category: Respiratory Medicine Authors: Berkman, Samuel A. Tapson, Victor F. Tags: Review Article Source Type: research